Lead Product(s) : Belinostat
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Acrotech Biopharma
Deal Size : $6.6 million
Deal Type : Agreement
Details : The new Agreement grants Acrotech a royalty-free license to belinostat in all other territories including the United States, Canada, Mexico, and India.
Product Name : Undisclosed
Product Type : Cytotoxic Drug
Upfront Cash : $6.6 million
April 06, 2020
Lead Product(s) : Belinostat
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Acrotech Biopharma
Deal Size : $6.6 million
Deal Type : Agreement
Reset All
